Skip to main content
. 2017 Jun 28;8(49):85014–85023. doi: 10.18632/oncotarget.18777

Figure 1. Linc00152 was downregulated by oxLDL treatment in HUVECs in a dose- and time-dependent manner.

Figure 1

(A) Linc00152 was downregulated by oxLDL treatment in HUVECs in a dose-dependent manner. HUVECs were subcultured in 12-well culture plates. On reaching 50% confluence, ox-LDL was added into the cells at final concentrations of 50, 100, 150 and 200 μg/mL. As a control, the cells were incubated with an equal volume of PBS. After incubation for 24 h, the expression of linc00152 was detected by qPCR. (B) Linc00152 was downregulated by oxLDL treatment in HUVECs in a time-dependent manner. HUVECs were incubated with 150 μg/mL ox-LDL. At the time points 6 h, 12 h, 24 h, 36 h and 48 h, the expression of linc00152 was detected by qPCR. *P < 0.05, **P < 0.01.